Detail akcie Pulse Biosciences online

Business Summary: Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Pulse Biosciences Inc revenues was not reported. Net loss increased 27% to $53.6M. Higher net loss reflects Stock-based Compensation in SGA increase of 98% to $7.3M (expense), Stock-based Compensation in R&D increase of 80% to $6.3M (expense), Research & Development exp increase of 7% to $26M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.88 to -$0.92.